Drugs / Lianhua Qingke tablets
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05625022 | Nov 2022 → Jun 2023 | Coronaviridae infectious disease | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lianhua Qingke tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05625022 ↗ |